Trials Sponsors Conditions Drugs Pricing

Conditions

Cancer Geographic Tongue

Keywords

antiangiogenic drugsglossitis benign migratory

Outcome Measures

Primary Outcomes (1)

Benign migratory glossitis
erythematous erosions, with loss of filiform papillae, surrounded by white circinate rims on the dorsal tongue
From enrollment to the end of study at 7 years

Secondary Outcomes (1)

Adverse events
From enrollment to the end of study at 7 years

Study Arms (1)

angiogenesis inhibitors

Oral clinical manifestation

Other: Clinical evaluation

Interventions

Clinical evaluationOther

treatment methods, associated symptoms, evolution and clinical presentation

Also known as: clinical images

angiogenesis inhibitors

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Sexall

Healthy VolunteersNo

Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Hospital -Instituto do Cancer do Estado de Sao Paulo-ICESP

You may qualify if:

patient's charts which underwent antiangiogenic targeted drugs

You may not qualify if:

Sponsors & Collaborators

Instituto do Cancer do Estado de São Paulo
Otherlead

Study Sites (1)

Instituto do Cancer do Estado de São Paulo

São Paulo, São Paulo, 01246-000, Brazil

MeSH Terms

Conditions

NeoplasmsGlossitis, Benign Migratory

Condition Hierarchy (Ancestors)

GlossitisTongue DiseasesMouth DiseasesStomatognathic Diseases

Study Officials

Mauricio Neves Gomes, PhD
Instituto do Cancer do Estado de São Paulo
PRINCIPAL INVESTIGATOR
Wagner Gomes da Silva, PhD
Instituto do Cancer do Estado de São Paulo
PRINCIPAL INVESTIGATOR

Enrollment

8 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: CASE ONLY
Time Perspective: RETROSPECTIVE
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Assistant, Dental Oncology Service, Instituto do Câncer do Estado de São Paulo (ICESP-FMUSP)

Study Record Dates

First Submitted

May 1, 2025

First Posted

May 25, 2025

Study Start

July 16, 2017

Actual (reported)

Benign Migratory Glossitis Associated With Antiangiogenic Drugs

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (1)

angiogenesis inhibitors

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (1)

angiogenesis inhibitors

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Source record

Locations